Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
about
Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaBurkitt lymphoma in adolescents and young adults: management challenges.New Therapeutic Strategies in Acute Lymphocytic Leukemia.Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysisSpectral-spatial feature-based neural network method for acute lymphoblastic leukemia cell identification via microscopic hyperspectral imaging technology.Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia.Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use.Role of new Immunophenotypic Markers on Prognostic and Overall Survival of Acute Myeloid Leukemia: a Systematic Review and Meta-AnalysisPostremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL.Evolution of Tumor Clones in Adult Acute Lymphoblastic Leukemia.Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.Immunophenotypic aberrancies in acute lymphoblastic leukemia from 282 Iraqi patients.Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.Immunotherapy approaches to treat adult acute lymphoblastic leukemia.Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsIs Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.Minimal residual disease detection using flow cytometry: Applications in acute leukemia.Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003.Pediatric T-cell acute lymphoblastic leukemia.VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.Continuing challenges and current issues in acute lymphoblastic leukemia.Acute lymphoblastic leukemia: a comprehensive review and 2017 updateWhen Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia.Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.Impact of pretransplant minimal residual disease on the post-transplant outcome of pediatric acute lymphoblastic leukemia.Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.Qualitative polymerase chain reaction versus quantitative polymerase chain reaction for the detection of minimal residual disease in children with acute lymphoblastic leukemia.Role of peripheral blood minimum residual disease at day 8 of induction therapy in high-risk pediatric patients with acute lymphocytic leukemiaNext Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL.Antigen receptor sequencing of paired bone marrow samples shows homogeneous distribution of acute lymphoblastic leukemia subclones.
P2860
Q26751269-762401B2-EFE0-429F-A00D-AE6E31D91494Q30238965-0AD8D5E9-4FFA-40AE-ACAD-49FBAB9EB1ECQ30252776-D10D2E7B-514D-4CB8-B1A3-9ADC70BDCDCDQ33815986-890EB69B-6EA8-4435-9A03-9119043AF0B5Q33824489-D74700F6-30DB-4413-B2B7-FC36190DA1F2Q36151241-3D430902-7873-4821-A890-3C13BA7C522AQ36169572-3D729CF9-E118-4787-B015-F942B702BD34Q36183310-8D6A93AF-6A48-4292-99FA-B235CD8AF423Q36413755-399C59CC-7E89-4501-8ABD-984104E37F4EQ36528379-5AE135B8-836B-40CF-A251-3249B0D6BF6BQ37101299-9DEEBF8B-509C-442B-B4F9-6864D683D340Q37544878-4C8546CD-08F5-4521-B243-E2FBA4E9E354Q37624584-F46B4E50-E366-4DA1-8D04-EE3FCE878439Q38655375-701E73E0-095D-4547-A19B-C6798C73ACCFQ38672607-3B54E97D-902C-44D5-B4D8-804308A13B4DQ38672646-8771A803-5114-423E-BBB7-6B70FF0C96ABQ38674589-348D9DBD-48A1-482A-844F-6A528996D152Q38674733-84C5006D-5C9F-46B5-927C-AC7CE685B985Q38756821-B668BC83-116A-4155-9B1D-011B8CBCB8EDQ38787405-80127162-B4B3-4440-BD1B-A957EC3AEB0DQ38789282-24A6748D-A2EA-4673-9D78-FC2C64253098Q38815331-EEE13C94-A712-4FFC-B914-F6201C7827E4Q38839367-6BA295E7-A644-496B-9EE8-2CB563822FCEQ38852472-5DD43428-C10E-49F3-9E70-55D6D7E0D9E2Q38909642-F0D44F15-A070-4BD6-BBE3-878F267167E0Q38956273-ECA6CB17-ADE7-4B8C-8B88-BAE5CFA964D6Q39103567-42FF68F1-8634-48A3-B100-C6E206BC174CQ39123286-1FD83146-F049-4734-B2F2-B10A5F73F38AQ39366299-08773F22-64B7-48AC-B942-3BF9F9578F3EQ39406969-8D99C16F-AC3C-4CC9-A0EB-1379930E9AB5Q39420711-3D265065-EE9B-4192-B53C-BA92FD1F408DQ40396529-8301A15E-93B7-4A8E-9931-F83B842369D9Q40591760-6E73EF01-8122-44C6-B912-358096C943A9Q40721566-3348A4D6-B0C7-4457-8AFD-3395A771EF72Q41246402-2A658A9D-EC63-4285-929A-6E0D5523305BQ41893098-C36CF7DC-FFFE-4500-997F-FE8212CC0620Q41981064-9369FBF9-8C0F-4735-AFA3-D253C0CAF620Q42050819-D9B8BE30-3239-4C04-B9D5-20E7012B4D3DQ42912272-410EAC41-808E-47F7-8753-2169EDB1BAE1Q43279252-CF3B0A2D-DCFA-4440-B6AF-7143C32717B6
P2860
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Minimal residual disease diagn ...... and standardized technologies
@ast
Minimal residual disease diagn ...... and standardized technologies
@en
Minimal residual disease diagn ...... and standardized technologies
@nl
type
label
Minimal residual disease diagn ...... and standardized technologies
@ast
Minimal residual disease diagn ...... and standardized technologies
@en
Minimal residual disease diagn ...... and standardized technologies
@nl
prefLabel
Minimal residual disease diagn ...... and standardized technologies
@ast
Minimal residual disease diagn ...... and standardized technologies
@en
Minimal residual disease diagn ...... and standardized technologies
@nl
P2093
P2860
P3181
P1433
P1476
Minimal residual disease diagn ...... and standardized technologies
@en
P2093
Alberto Orfao
Monika Brüggemann
Vincent H J van der Velden
P2860
P304
P3181
P356
10.1182/BLOOD-2015-03-580027
P407
P577
2015-05-21T00:00:00Z